MGNX MacroGenics Inc.

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:

    • The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 14, 2024, at 10:30 am ET.  MacroGenics’ management will also participate in one-on-one meetings.
    • TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Virtual). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, May 29, 2024, at 12:30 pm ET.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at /events.cfm.  The Company will maintain archived replays of these webcasts on its website for 30 days.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###



CONTACT:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,
EN
13/05/2024

Underlying

MGNXMacroGenics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MacroGenics Inc.

 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Pha...

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohortCompany expects to have mature median rPFS no later than early 2025MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate updat...

September 15, 2024 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congr...

MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024 MacroGenics to host investor call to review key data presented at ESMO on Monday, September 16, 2024, at 8:00 a.m. ET ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (m...

September 8, 2024 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Provides Update on Corporate Progress, Second Quarter 2024...

MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in SeptemberReceived $100.0 million in milestones related to Incyte’s advancement of ZYNYZ® (retifanlimab-dlwr) subsequent to quarter-endConfirming cash runway guidance into 2026 ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatm...

August 6, 2024 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Provides Vobramitamab Duocarmazine Update

MacroGenics Provides Vobramitamab Duocarmazine Update Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of 6-month rPFS rate and updated safetyTreatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing following review of totality of data, including efficacy, and emerging adverse events associated with prolonged exposure and considering potential risk/benefit to participants; ...

July 30, 2024 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Announces Achievement of $100 Million in Milestones Relate...

MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte Confirming cash runway guidance into 2026 ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the achievement of $100 million in milestones from Incyte Corporation related to development progress of ZYNYZ® (retifanlimab-dlwr), following an agreement on July 24, 202...

July 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch